Objective response (%)

Median of survival (month)

Pemetrexed

27%

9.6%

Docetaxel

13%

9%

Paclitaxel

10%

7%

Ifosfamide

5% - 20%

5.5%

Gemcitabine

11% - 23%

5.8%

Vinfluvine

9%

6.9%